Tesamorelin vs Sermorelin

An FDA-approved growth-hormone-releasing hormone analogue for HIV-associated lipodystrophy, used off-label for visceral fat reduction and metabolic health.

An FDA-approved growth-hormone-releasing hormone (GHRH) analogue that stimulates the pituitary to release natural GH. Staple of anti-aging clinics and the gateway GH secretagogue.

Tesamorelin is a stabilised GHRH analogue with a longer half-life than sermorelin. It selectively reduces visceral adipose tissue (VAT) while preserving subcutaneous fat and lean mass.

Sermorelin is the first 29 amino acids of endogenous GHRH — enough to bind the pituitary GHRH receptor and trigger physiological GH pulses. Unlike exogenous HGH, endogenous feedback loops remain intact.

1–2 mg subcutaneous daily

200–500 mcg subcutaneous at bedtime

~26 minutes

~11–12 minutes

Subcutaneous

Subcutaneous

approved

approved

Not yet listed

Not yet listed